Axsome Therapeutics, Inc. (AXSM) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Axsome Therapeutics (AXSM) Q1 2026: Ovelity Peak Sales Raised to $8B on Alzheimer’s Agitation Expansion
  May 04, 2026
• Axsome Therapeutics (AXSM) Q4 2025: Avelity Scripts Jump 42% as Commercial Platform Scales
  February 24, 2026
• Axsome (AXSM) Q3 2025: 63% Revenue Surge Anchors Pipeline-Driven Growth Trajectory
  November 03, 2025
• Axsome (AXSM) Q2 2025: Avelity Scripts Jump 15% as Coverage Expansion Drives Prescriber Uptake
  August 04, 2025
• Jazz Pharmaceuticals (JAZZ) Q1 2025: Chimerix Deal Adds $890M R&D Charge, Oncology Pipeline Readout Looms
  July 06, 2025
• Axsome Therapeutics (AXSM) Q3 2024: Avelity Prescriptions Surge 108% as Pipeline Readouts Near
  November 12, 2024
• Axsome Therapeutics (AXSM) Q2 2024: Avelity Prescriptions Surge 131% as Payer Access Expands by 22M Lives
  August 05, 2024
• Axsome Therapeutics (AXSM) Q1 2024: Avelity Prescriptions Jump 206% as Coverage Expands, Pipeline Milestones Stack Up
  May 06, 2024
• Axsome Therapeutics (AXSM) Q4 2023: Commercial Revenue Triples, Pipeline Execution Sets Up 5 Late-Stage Readouts
  January 04, 2024

Browse all companies